Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study

Authors: Wilfried Dinh, Mark Lankisch, Werner Nickl, Daniel Scheyer, Thomas Scheffold, Frank Kramer, Thomas Krahn, Rolf M Klein, Michael Coll Barroso, Reiner Füth

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Left ventricular diastolic dysfunction (LVDD) is considered a precursor of diabetic cardiomyopathy, while insulin resistance (IR) is a precursor of type 2 diabetes mellitus (T2DM) and independently predicts heart failure (HF). We assessed whether IR and abnormalities of the glucose metabolism are related to LVDD.

Methods

We included 208 patients with normal ejection fraction, 57 (27%) of whom had T2DM before inclusion. In subjects without T2DM, an oral glucose tolerance test (oGTT) was performed. IR was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). The lower limit of the top quartile of the HOMA-IR distribution (3.217) was chosen as threshold for IR. LVDD was verified according to current guidelines.

Results

IR was diagnosed in 38 (18%) patients without a history of diabetes. The prevalence of LVDD was 92% in subjects with IR vs. 72% in patients without IR (n = 113), respectively (p = 0.013). In the IR group, the early diastolic mitral inflow velocity (E) in relation to the early diastolic tissue Doppler velocity (averaged from the septal and lateral mitral annulus, E'av) ratio (E/E'av) was significantly higher compared to those without IR (9.8 [8.3-11.5] vs. 8.1 [6.6-11.0], p = 0.011). This finding remains significant when patients with IR and concomitant T2DM based on oGTT results were excluded (E/E'av ratio 9.8 [8.2-11.1)] in IR vs. 7.9 [6.5-10.5] in those without both IR and T2DM, p = 0.014). There were significant differences among patients with and without LVDD regarding the HOMA-IR (1.71 [1.04-3.88] vs. 1.09 [0.43-2.2], p = 0.003). The HOMA-IR was independently associated with LVDD on multivariate logistic regression analysis, a 1-unit increase in HOMA-IR value was associated with an odds ratio for prevalent LVDD of 2.1 (95% CI 1.3-3.1, p = 0.001). Furthermore, the E/E'av ratio increases along the glucose metabolism status from normal glucose metabolism (7.6 [6.2-10.1]) to impaired glucose tolerance (8.8 [7.4-11.0]) and T2DM (10.5 [8.1-13.2]), respectively (p < 0.001).

Conclusions

Insulin resistance is independently associated with LVDD in subjects without overt T2DM. Patients with IR and glucose metabolism disorders might represent a target population to prevent the development of HF. Screening programs for glucose metabolism disturbances should address the assessment of diastolic function and probably IR.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008, 10: 933-989. 10.1016/j.ejheart.2008.08.005.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008, 10: 933-989. 10.1016/j.ejheart.2008.08.005.CrossRefPubMed
2.
go back to reference Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006, 355: 260-269. 10.1056/NEJMoa051530.CrossRefPubMed Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006, 355: 260-269. 10.1056/NEJMoa051530.CrossRefPubMed
3.
go back to reference Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006, 355: 251-259. 10.1056/NEJMoa052256.CrossRefPubMed Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006, 355: 251-259. 10.1056/NEJMoa052256.CrossRefPubMed
4.
go back to reference Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Goetze JP, Jensen JS: Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation. 2009, 119: 2679-2685. 10.1161/CIRCULATIONAHA.108.793471.CrossRefPubMed Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Goetze JP, Jensen JS: Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation. 2009, 119: 2679-2685. 10.1161/CIRCULATIONAHA.108.793471.CrossRefPubMed
5.
go back to reference Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature. 2001, 414: 782-787. 10.1038/414782a.CrossRefPubMed Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature. 2001, 414: 782-787. 10.1038/414782a.CrossRefPubMed
6.
go back to reference Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L: The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005, 28: 612-616. 10.2337/diacare.28.3.612.CrossRefPubMed Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L: The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005, 28: 612-616. 10.2337/diacare.28.3.612.CrossRefPubMed
7.
go back to reference Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972, 30: 595-602. 10.1016/0002-9149(72)90595-4.CrossRefPubMed Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972, 30: 595-602. 10.1016/0002-9149(72)90595-4.CrossRefPubMed
8.
go back to reference Raev DC: Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care. 1994, 17: 633-639. 10.2337/diacare.17.7.633.CrossRefPubMed Raev DC: Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care. 1994, 17: 633-639. 10.2337/diacare.17.7.633.CrossRefPubMed
9.
go back to reference Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama. 2003, 289: 194-202. 10.1001/jama.289.2.194.CrossRefPubMed Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama. 2003, 289: 194-202. 10.1001/jama.289.2.194.CrossRefPubMed
10.
go back to reference Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA: Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol. 2001, 87: 320-323. 10.1016/S0002-9149(00)01366-7.CrossRefPubMed Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA: Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol. 2001, 87: 320-323. 10.1016/S0002-9149(00)01366-7.CrossRefPubMed
11.
go back to reference Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungen HD, Scherer M, Kochen MM, Binder L, Herrmann-Lingen C, Gelbrich G: Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia. 53: 1331-1340. 10.1007/s00125-010-1718-8. Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungen HD, Scherer M, Kochen MM, Binder L, Herrmann-Lingen C, Gelbrich G: Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia. 53: 1331-1340. 10.1007/s00125-010-1718-8.
12.
go back to reference Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004, 53: 1782-1789. 10.2337/diabetes.53.7.1782.CrossRefPubMed Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004, 53: 1782-1789. 10.2337/diabetes.53.7.1782.CrossRefPubMed
13.
go back to reference Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002, 25: 1135-1141. 10.2337/diacare.25.7.1135.CrossRefPubMed Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002, 25: 1135-1141. 10.2337/diacare.25.7.1135.CrossRefPubMed
14.
go back to reference Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L: Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005, 46: 2054-2060. 10.1016/j.jacc.2005.07.059.CrossRefPubMed Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L: Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005, 46: 2054-2060. 10.1016/j.jacc.2005.07.059.CrossRefPubMed
15.
go back to reference Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G: High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003, 46: 182-189.PubMed Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G: High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003, 46: 182-189.PubMed
16.
go back to reference Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG: Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004, 43: 1399-1404. 10.1016/j.jacc.2003.10.062.CrossRefPubMed Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG: Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004, 43: 1399-1404. 10.1016/j.jacc.2003.10.062.CrossRefPubMed
17.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18: 1440-1463. 10.1016/j.echo.2005.10.005.CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18: 1440-1463. 10.1016/j.echo.2005.10.005.CrossRefPubMed
18.
go back to reference Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10: 165-193. 10.1093/ejechocard/jep007.CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10: 165-193. 10.1093/ejechocard/jep007.CrossRefPubMed
19.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.CrossRefPubMed
20.
go back to reference Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85: 2402-2410. 10.1210/jc.85.7.2402.CrossRefPubMed Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85: 2402-2410. 10.1210/jc.85.7.2402.CrossRefPubMed
21.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.
22.
go back to reference Paulus WJ, van Ballegoij JJ: Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 55: 526-537. 10.1016/j.jacc.2009.06.067. Paulus WJ, van Ballegoij JJ: Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 55: 526-537. 10.1016/j.jacc.2009.06.067.
23.
go back to reference Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, Barroso MC, Lankisch M: Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009, 8: 58-10.1186/1475-2840-8-58.PubMedCentralCrossRefPubMed Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, Barroso MC, Lankisch M: Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009, 8: 58-10.1186/1475-2840-8-58.PubMedCentralCrossRefPubMed
24.
go back to reference Futh R, Dinh W, Nickl W, Bansemir L, Barroso MC, Bufe A, Sause A, Scheffold T, Krahn T, Ellinghaus P, Lankisch M: Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol. 2009, 14: e76-79.PubMedCentralPubMed Futh R, Dinh W, Nickl W, Bansemir L, Barroso MC, Bufe A, Sause A, Scheffold T, Krahn T, Ellinghaus P, Lankisch M: Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol. 2009, 14: e76-79.PubMedCentralPubMed
25.
go back to reference He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001, 161: 996-1002. 10.1001/archinte.161.7.996.CrossRefPubMed He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001, 161: 996-1002. 10.1001/archinte.161.7.996.CrossRefPubMed
26.
go back to reference Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974, 34: 29-34. 10.1016/0002-9149(74)90089-7.CrossRefPubMed Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974, 34: 29-34. 10.1016/0002-9149(74)90089-7.CrossRefPubMed
27.
go back to reference Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. Jama. 2005, 294: 334-341. 10.1001/jama.294.3.334.CrossRefPubMed Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. Jama. 2005, 294: 334-341. 10.1001/jama.294.3.334.CrossRefPubMed
28.
go back to reference Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB: Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002, 105: 1928-1933. 10.1161/01.CIR.0000015076.37047.D9.CrossRefPubMed Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB: Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002, 105: 1928-1933. 10.1161/01.CIR.0000015076.37047.D9.CrossRefPubMed
29.
go back to reference Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE: Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol. 2003, 41: 820-826. 10.1016/S0735-1097(02)02921-2.CrossRefPubMed Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE: Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol. 2003, 41: 820-826. 10.1016/S0735-1097(02)02921-2.CrossRefPubMed
30.
go back to reference From AM, Scott CG, Chen HH: The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 55: 300-305. 10.1016/j.jacc.2009.12.003. From AM, Scott CG, Chen HH: The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 55: 300-305. 10.1016/j.jacc.2009.12.003.
31.
go back to reference Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation. 2007, 115: 3213-3223. 10.1161/CIRCULATIONAHA.106.679597.CrossRefPubMed Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation. 2007, 115: 3213-3223. 10.1161/CIRCULATIONAHA.106.679597.CrossRefPubMed
32.
go back to reference Kass DA, Bronzwaer JG, Paulus WJ: What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res. 2004, 94: 1533-1542. 10.1161/01.RES.0000129254.25507.d6.CrossRefPubMed Kass DA, Bronzwaer JG, Paulus WJ: What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res. 2004, 94: 1533-1542. 10.1161/01.RES.0000129254.25507.d6.CrossRefPubMed
33.
go back to reference van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006, 113: 1966-1973. 10.1161/CIRCULATIONAHA.105.587519.CrossRefPubMed van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006, 113: 1966-1973. 10.1161/CIRCULATIONAHA.105.587519.CrossRefPubMed
34.
go back to reference Stanley WC, Lopaschuk GD, McCormack JG: Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997, 34: 25-33. 10.1016/S0008-6363(97)00047-3.CrossRefPubMed Stanley WC, Lopaschuk GD, McCormack JG: Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997, 34: 25-33. 10.1016/S0008-6363(97)00047-3.CrossRefPubMed
35.
go back to reference Bronzwaer JG, Paulus WJ: Nitric oxide: the missing lusitrope in failing myocardium. Eur Heart J. 2008, 29: 2453-2455. 10.1093/eurheartj/ehn393.CrossRefPubMed Bronzwaer JG, Paulus WJ: Nitric oxide: the missing lusitrope in failing myocardium. Eur Heart J. 2008, 29: 2453-2455. 10.1093/eurheartj/ehn393.CrossRefPubMed
36.
go back to reference Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH: Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 1988, 62: 535-542.CrossRefPubMed Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH: Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 1988, 62: 535-542.CrossRefPubMed
37.
go back to reference Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991, 87: 2246-2252. 10.1172/JCI115260.PubMedCentralCrossRefPubMed Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991, 87: 2246-2252. 10.1172/JCI115260.PubMedCentralCrossRefPubMed
38.
go back to reference Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, Williams GH: Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest. 1994, 94: 2295-2300. 10.1172/JCI117593.PubMedCentralCrossRefPubMed Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, Williams GH: Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest. 1994, 94: 2295-2300. 10.1172/JCI117593.PubMedCentralCrossRefPubMed
39.
go back to reference Sartori M, Ceolotto G, Papparella I, Baritono E, Ciccariello L, Calo L, Leoni M, Semplicini A: Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens. 2004, 17: 604-610. 10.1016/j.amjhyper.2004.02.017.CrossRefPubMed Sartori M, Ceolotto G, Papparella I, Baritono E, Ciccariello L, Calo L, Leoni M, Semplicini A: Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens. 2004, 17: 604-610. 10.1016/j.amjhyper.2004.02.017.CrossRefPubMed
40.
go back to reference Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001, 133: 687-694. 10.1038/sj.bjp.0704131.PubMedCentralCrossRefPubMed Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001, 133: 687-694. 10.1038/sj.bjp.0704131.PubMedCentralCrossRefPubMed
41.
go back to reference Park JS, Nam JS, Cho MH, Yoo JS, Ahn CW, Jee SH, Lee HS, Cha BS, Kim KR, Lee HC: Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause. 17: 779-784. Park JS, Nam JS, Cho MH, Yoo JS, Ahn CW, Jee SH, Lee HS, Cha BS, Kim KR, Lee HC: Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause. 17: 779-784.
42.
go back to reference MacIsaac RJ, Thomas MC, Panagiotopoulos S, Smith TJ, Hao H, Matthews DG, Jerums G, Burrell LM, Srivastava PM: Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2008, 7: 15-10.1186/1475-2840-7-15.PubMedCentralCrossRefPubMed MacIsaac RJ, Thomas MC, Panagiotopoulos S, Smith TJ, Hao H, Matthews DG, Jerums G, Burrell LM, Srivastava PM: Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2008, 7: 15-10.1186/1475-2840-7-15.PubMedCentralCrossRefPubMed
43.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMicm066227.CrossRefPubMed Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMicm066227.CrossRefPubMed
44.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.CrossRefPubMed
45.
go back to reference Carson P, Johnson G, Fletcher R, Cohn J: Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol. 1996, 27: 642-649. 10.1016/0735-1097(95)00503-X.CrossRefPubMed Carson P, Johnson G, Fletcher R, Cohn J: Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol. 1996, 27: 642-649. 10.1016/0735-1097(95)00503-X.CrossRefPubMed
46.
go back to reference Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006, 27: 2338-2345. 10.1093/eurheartj/ehl250.CrossRefPubMed Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006, 27: 2338-2345. 10.1093/eurheartj/ehl250.CrossRefPubMed
47.
go back to reference Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008, 359: 2456-2467. 10.1056/NEJMoa0805450.CrossRefPubMed Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008, 359: 2456-2467. 10.1056/NEJMoa0805450.CrossRefPubMed
48.
go back to reference Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003, 362: 777-781. 10.1016/S0140-6736(03)14285-7.CrossRefPubMed Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003, 362: 777-781. 10.1016/S0140-6736(03)14285-7.CrossRefPubMed
49.
go back to reference Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005, 353: 2643-2653. 10.1056/NEJMoa052187.CrossRefPubMed Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005, 353: 2643-2653. 10.1056/NEJMoa052187.CrossRefPubMed
50.
go back to reference Piccini JP, Klein L, Gheorghiade M, Bonow RO: New insights into diastolic heart failure: role of diabetes mellitus. Am J Med. 2004, 116 (Suppl 5A): 64S-75S. 10.1016/j.amjmed.2003.10.021.CrossRefPubMed Piccini JP, Klein L, Gheorghiade M, Bonow RO: New insights into diastolic heart failure: role of diabetes mellitus. Am J Med. 2004, 116 (Suppl 5A): 64S-75S. 10.1016/j.amjmed.2003.10.021.CrossRefPubMed
51.
go back to reference von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM: Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res. 2008, 5: 310-318. 10.3132/dvdr.2008.045.CrossRefPubMed von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM: Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res. 2008, 5: 310-318. 10.3132/dvdr.2008.045.CrossRefPubMed
52.
go back to reference Edelmann F, Pieske B: Diastolic Heart Failure. Diagnosis, Therapy and Impact of Exercise Training. Deutsche Zeitschrift für Sportmedizin. 50: 192-199. Edelmann F, Pieske B: Diastolic Heart Failure. Diagnosis, Therapy and Impact of Exercise Training. Deutsche Zeitschrift für Sportmedizin. 50: 192-199.
53.
go back to reference DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-223.PubMed DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-223.PubMed
54.
go back to reference Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999, 22: 818-822. 10.2337/diacare.22.5.818.CrossRefPubMed Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999, 22: 818-822. 10.2337/diacare.22.5.818.CrossRefPubMed
Metadata
Title
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study
Authors
Wilfried Dinh
Mark Lankisch
Werner Nickl
Daniel Scheyer
Thomas Scheffold
Frank Kramer
Thomas Krahn
Rolf M Klein
Michael Coll Barroso
Reiner Füth
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-63

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.